817 related articles for article (PubMed ID: 19604078)
1. A lentiviral vector that activates latent human immunodeficiency virus-1 proviruses by the overexpression of tat and that kills the infected cells.
Macías D; Oya R; Saniger L; Martín F; Luque F
Hum Gene Ther; 2009 Nov; 20(11):1259-68. PubMed ID: 19604078
[TBL] [Abstract][Full Text] [Related]
2. StpC-based gene therapy targeting latent reservoirs of HIV-1.
Turner LS; Tsygankov AY; Henderson EE
Antiviral Res; 2006 Dec; 72(3):233-41. PubMed ID: 16891001
[TBL] [Abstract][Full Text] [Related]
3. HIV Provirus Stably Reproduces Parental Latent and Induced Transcription Phenotypes Regardless of the Chromosomal Integration Site.
Hashemi FB; Barreto K; Bernhard W; Hashemi P; Lomness A; Sadowski I
J Virol; 2016 Jun; 90(11):5302-14. PubMed ID: 26984732
[TBL] [Abstract][Full Text] [Related]
4. 5' long terminal repeat (LTR)-selective methylation of latently infected HIV-1 provirus that is demethylated by reactivation signals.
Ishida T; Hamano A; Koiwa T; Watanabe T
Retrovirology; 2006 Oct; 3():69. PubMed ID: 17034647
[TBL] [Abstract][Full Text] [Related]
5. Development of 5' LTR DNA methylation of latent HIV-1 provirus in cell line models and in long-term-infected individuals.
Trejbalová K; Kovářová D; Blažková J; Machala L; Jilich D; Weber J; Kučerová D; Vencálek O; Hirsch I; Hejnar J
Clin Epigenetics; 2016; 8():19. PubMed ID: 26900410
[TBL] [Abstract][Full Text] [Related]
6. Long Noncoding RNA uc002yug.2 Activates HIV-1 Latency through Regulation of mRNA Levels of Various RUNX1 Isoforms and Increased Tat Expression.
Huan C; Li Z; Ning S; Wang H; Yu XF; Zhang W
J Virol; 2018 May; 92(9):. PubMed ID: 29491162
[TBL] [Abstract][Full Text] [Related]
7. Acquisition of HIV-1 resistance in T lymphocytes using an ACA-specific E. coli mRNA interferase.
Chono H; Matsumoto K; Tsuda H; Saito N; Lee K; Kim S; Shibata H; Ageyama N; Terao K; Yasutomi Y; Mineno J; Kim S; Inouye M; Kato I
Hum Gene Ther; 2011 Jan; 22(1):35-43. PubMed ID: 20649483
[TBL] [Abstract][Full Text] [Related]
8. Inhibition by interferon of herpes simplex virus type 1-activated transcription of tat-defective provirus.
Popik W; Pitha PM
Proc Natl Acad Sci U S A; 1991 Nov; 88(21):9573-7. PubMed ID: 1719535
[TBL] [Abstract][Full Text] [Related]
9. Regulation of human immunodeficiency virus-1 latency and its reactivation.
Verdin E
Bull Mem Acad R Med Belg; 2008; 163(6):355-64; discussion 364-5. PubMed ID: 19445107
[TBL] [Abstract][Full Text] [Related]
10. The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency.
Mousseau G; Kessing CF; Fromentin R; Trautmann L; Chomont N; Valente ST
mBio; 2015 Jul; 6(4):e00465. PubMed ID: 26152583
[TBL] [Abstract][Full Text] [Related]
11. Infection of human brain cells by HIV-1: restricted virus production in chronically infected human glial cell lines.
Brack-Werner R; Kleinschmidt A; Ludvigsen A; Mellert W; Neumann M; Herrmann R; Khim MC; Burny A; Müller-Lantzsch N; Stavrou D
AIDS; 1992 Mar; 6(3):273-85. PubMed ID: 1373627
[TBL] [Abstract][Full Text] [Related]
12. Sustained induction of NF-kappa B is required for efficient expression of latent human immunodeficiency virus type 1.
Williams SA; Kwon H; Chen LF; Greene WC
J Virol; 2007 Jun; 81(11):6043-56. PubMed ID: 17376917
[TBL] [Abstract][Full Text] [Related]
13. The Molecular Basis for Human Immunodeficiency Virus Latency.
Mbonye U; Karn J
Annu Rev Virol; 2017 Sep; 4(1):261-285. PubMed ID: 28715973
[TBL] [Abstract][Full Text] [Related]
14. Synergy between human immunodeficiency virus type 1 and Epstein-Barr virus in T lymphoblastoid cell lines.
Zhang RD; Guan M; Park Y; Tawadros R; Yang JY; Gold B; Wu B; Henderson EE
AIDS Res Hum Retroviruses; 1997 Jan; 13(2):161-71. PubMed ID: 9007201
[TBL] [Abstract][Full Text] [Related]
15. Mathematical model of the Tat-Rev regulation of HIV-1 replication in an activated cell predicts the existence of oscillatory dynamics in the synthesis of viral components.
Likhoshvai VA; Khlebodarova TM; Bazhan SI; Gainova IA; Chereshnev VA; Bocharov GA
BMC Genomics; 2014; 15 Suppl 12(Suppl 12):S1. PubMed ID: 25564443
[TBL] [Abstract][Full Text] [Related]
16. Human immunodeficiency virus (HIV) type 2-mediated inhibition of HIV type 1: a new approach to gene therapy of HIV-infection.
Arya SK; Gallo RC
Proc Natl Acad Sci U S A; 1996 Apr; 93(9):4486-91. PubMed ID: 8633095
[TBL] [Abstract][Full Text] [Related]
17. Antitat gene therapy: a candidate for late-stage AIDS patients.
Lisziewicz J; Sun D; Lisziewicz A; Gallo RC
Gene Ther; 1995 May; 2(3):218-22. PubMed ID: 7614253
[TBL] [Abstract][Full Text] [Related]
18. Human immunodeficiency virus-1 tat- and tat/nef-defective genomes containing HIV-regulated diphtheria toxin A chain gene inhibit HIV replication.
Brdar B; Matulić M; Rubelj I; Ivanković M; Reich E
Croat Med J; 2002 Oct; 43(5):591-7. PubMed ID: 12402403
[TBL] [Abstract][Full Text] [Related]
19. Inducible expression of the deltaNGFr/F12Nef fusion protein as a new tool for anti-human immunodeficiency virus type 1 gene therapy.
Muratori C; Schiavoni I; Melucci-Vigo G; Olivetta E; Santarcangelo AC; Pugliese K; Verani P; Federico M
Hum Gene Ther; 2002 Sep; 13(14):1751-66. PubMed ID: 12396627
[TBL] [Abstract][Full Text] [Related]
20. Activation of tat-defective human immunodeficiency virus by ultraviolet light.
Sadaie MR; Tschachler E; Valerie K; Rosenberg M; Felber BK; Pavlakis GN; Klotman ME; Wong-Staal F
New Biol; 1990 May; 2(5):479-86. PubMed ID: 1981148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
